OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in denmark and sweden

K.l. Grøn; E. Arkema; B. Glintborg; F. Mehnert; M. Østergaard; L. Dreyer; M. Nørgaard; N.s. Krogh; J. Askling; M. Heltand

doi:10.1136/annrheumdis-2018-eular.2389

OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in denmark and sweden

K.l. Grøn, E. Arkema, B. Glintborg, F. Mehnert, M. Østergaard, L. Dreyer, M. Nørgaard, N.s. Krogh, J. Askling, M. Heltand

Originalsprog	Engelsk
Publikationsdato	2018
Antal sider	1
DOI	https://doi.org/10.1136/annrheumdis-2018-eular.2389
Status	Udgivet - 2018

Adgang til dokumentet

10.1136/annrheumdis-2018-eular.2389

208.1.full.pdfForlagets udgivne version, 487 KB

Citationsformater

@conference{3d0cd90a341143b39676bce1f471bb10,

title = "OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in denmark and sweden",

author = "K.l. Gr{\o}n and E. Arkema and B. Glintborg and F. Mehnert and M. {\O}stergaard and L. Dreyer and M. N{\o}rgaard and N.s. Krogh and J. Askling and M. Heltand",

year = "2018",

doi = "10.1136/annrheumdis-2018-eular.2389",

language = "English",

pages = "208--208",

}

TY - ABST

T1 - OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in denmark and sweden

AU - Grøn, K.l.

AU - Arkema, E.

AU - Glintborg, B.

AU - Mehnert, F.

AU - Østergaard, M.

AU - Dreyer, L.

AU - Nørgaard, M.

AU - Krogh, N.s.

AU - Askling, J.

AU - Heltand, M.

PY - 2018

Y1 - 2018

U2 - 10.1136/annrheumdis-2018-eular.2389

DO - 10.1136/annrheumdis-2018-eular.2389

M3 - Conference abstract for conference

SP - 208

EP - 208

ER -